Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Novartis
Novartis
Kivu Bioscience Inc.
Bayer
University of California, Irvine
Eastern Cooperative Oncology Group
ViroMissile, Inc.
Dana-Farber Cancer Institute
Washington University School of Medicine
Essen Biotech
MacroGenics
Avacta Life Sciences Ltd
Alliance for Clinical Trials in Oncology
Institut Curie
University of Nebraska
Adela, Inc
Var2 Pharmaceuticals
Memorial Sloan Kettering Cancer Center
Mayo Clinic
Tanabe Pharma America, Inc.
Hadassah Medical Organization
British Columbia Cancer Agency
Washington University School of Medicine
GONGCHU Biotechnology Co., Ltd
Jonsson Comprehensive Cancer Center
University of California, Irvine
German Cancer Research Center
University Health Network, Toronto
Institut du Cancer de Montpellier - Val d'Aurelle
Stanford University
Northwestern University
BostonGene
Institut du Cancer de Montpellier - Val d'Aurelle
University of California, Davis
Second Affiliated Hospital of Guangzhou Medical University
Innolake Biopharm